Please assess the completion status of the following clinical trial:

Trial Title: Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neutropenia~* Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4 times per month~* Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain Inventory (BPI)~Exclusion Criteria:~* Other sources of chronic pain~* Previously tried loratadine for 7 consecutive days or more for bone pain~* Allergy to loratadine~* Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Loratadine first (Type: EXPERIMENTAL): Take treatment daily for 7 days.
- Placebo first (Type: PLACEBO_COMPARATOR): Take placebo daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).